HT-ALZ Showed Improvement on Several Tests of Cognitive Function
HT-ALZ Showed Positive Benefits with Reductions in Anxiety
Completed Dose Response Study Leads Hoth to Begin Formulation Development
Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's Disease
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here